IMMUNOREACTIVITY FOR P53 PROTEIN IN MALIGNANT MESOTHELIOMA AND NONNEOPLASTIC MESOTHELIUM

被引:57
|
作者
RAMAEL, M
LEMMENS, G
EERDEKENS, C
BUYSSE, C
DEBLIER, I
JACOBS, W
VANMARCK, E
机构
[1] Department of Pathology, University Hospital Antwerp, University of Antwerp (U.I. A.), Edegem, 2650
来源
JOURNAL OF PATHOLOGY | 1992年 / 168卷 / 04期
关键词
MESOTHELIOMA; P53; PROTEIN; SUPPRESSOR ONCOGENE; IMMUNOHISTOCHEMISTRY; MESOTHELIUM;
D O I
10.1002/path.1711680406
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The presence of p53 protein in non-neoplastic pleural mesothelium (40 cases) and in human malignant mesothelioma (36 cases) was assessed immunohistochemically using the antibodies DO7, CM-1, and PAb240. In a quarter of the malignant mesotheliomas, there was nuclear immunoreactivity for p53 protein with both the DO7 and CM-I antibodies. There were no statistically significant differences between the various mesothelioma subtypes (P>0.05). No immunoreactivity was found with the PAb240 antibody, suggesting absence of mutant-type p53 protein. Non-neoplastic mesothelium was not immunoreactive with any of the antibodies. We conclude that there is immunoreactivity for p53 protein in some mesotheliomas. p53 protein immunoreactivity could be used to discriminate between neoplastic and reactive mesothelium.
引用
收藏
页码:371 / 375
页数:5
相关论文
共 50 条
  • [21] Immunoreactivity of p53 nuclear protein in differentiated thyroid cancer
    Dedov, II
    Gerasimov, GA
    Bronshtein, MI
    Aleksandrova, GF
    Troshina, EA
    Figge, J
    BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE, 1996, 122 (12) : 1208 - 1209
  • [22] p53 gene mutations in squamous cell carcinoma occurring in scars - Comparison with p53 protein immunoreactivity
    Sakatani, S
    Kusakabe, H
    Kiyokane, K
    Suzuki, K
    AMERICAN JOURNAL OF DERMATOPATHOLOGY, 1998, 20 (05) : 463 - 467
  • [24] p53 autoantibodies in patients with malignant mesothelioma: stability through disease progression
    J Creaney
    B M McLaren
    S Stevenson
    A W Musk
    N de Klerk
    B W S Robinson
    R A Lake
    British Journal of Cancer, 2001, 84 : 52 - 56
  • [25] P53 IMMUNOREACTIVITY IN CARCINOSARCOMA OF THE ESOPHAGUS
    CASSON, AG
    KERKVLIET, N
    OMALLEY, F
    INCULET, R
    TROSTER, M
    JOURNAL OF SURGICAL ONCOLOGY, 1994, 56 (02) : 132 - 135
  • [26] p53 autoantibodies in patients with malignant mesothelioma: stability through disease progression
    Creaney, J
    McLaren, BM
    Stevenson, S
    Musk, AW
    de Klerk, N
    Robinson, BWS
    Lake, RA
    BRITISH JOURNAL OF CANCER, 2001, 84 (01) : 52 - 56
  • [27] Synovial membrane p53 protein immunoreactivity in rheumatoid arthritis patients
    Lee, CS
    Portek, L
    Edmonds, J
    Kirkham, B
    ANNALS OF THE RHEUMATIC DISEASES, 2000, 59 (02) : 143 - 145
  • [28] The role of P53 gene and p53 protein in non-Hodgkin malignant lymphoma.
    Gorecki, Gabriel Petre
    Nica-Badea, Delia
    Udristioiu, Aurelian
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (23_SUPPL) : TPS177 - TPS177
  • [29] KERATIN EXPRESSION IN NORMAL MESOTHELIUM AND MALIGNANT MESOTHELIOMA
    POLLOCK, L
    ABBOTT, C
    VANDERWALT, J
    SHEPPARD, M
    LEIGHT, I
    JOURNAL OF PATHOLOGY, 1991, 163 (02): : A164 - A164
  • [30] Serum p53 Antibody Is Not Associated with p53 Immunoreactivity in Patients with Pancreatobiliary Cancers
    Umeda, Junko
    Itoi, Takao
    Sofuni, Atsushi
    Itokawa, Fumihide
    Kurihara, Toshio
    Tsuchiya, Takayoshi
    Ishii, Kentaro
    Tsuji, Shujiro
    Ikeuchi, Nobuhito
    Tanaka, Reina
    Tonozuka, Ryosuke
    Honjo, Mitsuyoshi
    Mukai, Shuntaro
    Nagao, Toshitaka
    Oshiro, Hisashi
    Moriyasu, Fuminori
    JOURNAL OF ONCOLOGY, 2013, 2013